CCND1 and cancer: In a comprehensive analysis of three large databases (TCGA, Memorial Sloan Kettering Cancer Cancer (MSKCC) databases, and Geneplus cohort), it was revealed that CCND1 amplifications in patients that receive ICIs is associated with decreased OS in different cancer entities.